Ongoing research on RAD51D includes studies on its role in DNA repair, the development of targeted therapies, and the impact of its mutations on cancer risk. Clinical trials are also underway to evaluate the efficacy of PARP inhibitors in treating RAD51D-associated cancers. These studies aim to improve our understanding of RAD51D and enhance patient outcomes.
